European Notebook: Shake-Up At EMA, Restructuring At Pierre Fabre, Reinhardt Returns To Novartis
A new leadership team at EMA to be unveiled in September; the death of Pierre Fabre leads to management restructuring at France's third largest pharma; Reinhardt to review strategy as he replaces Vasella at the Swiss multinational, Novartis; and more…
You may also be interested in...
Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.
Roche’s Perjeta suffered a knock-back in Europe when NICE said the clinical trial population was not wholly relevant to the patient population in the UK.
The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.